000099078 001__ 99078 000099078 005__ 20240118091947.0 000099078 0247_ $$2doi$$a10.1155/2020/3495082 000099078 0248_ $$2sideral$$a122347 000099078 037__ $$aART-2020-122347 000099078 041__ $$aeng 000099078 100__ $$0(orcid)0000-0002-8100-5596$$aMartínez-Beamonte, R.$$uUniversidad de Zaragoza 000099078 245__ $$aDiet and Lifestyle in Nonalcoholic Fatty Liver Disease 000099078 260__ $$c2020 000099078 5060_ $$aAccess copy available to the general public$$fUnrestricted 000099078 5203_ $$aThe liver is an essential metabolic organ which governs body energy metabolism connected with adipose tissue and skeletal muscle among other tissues. The prevalence of obesity has reached epidemic proportions in many countries around the world and continues to grow every year which is caused by multiple factors, with diet and lifestyle being the most researched and therefore most important. Nonalcoholic fatty liver disease (NAFLD) is one of the several metabolic complications associated with obesity. The pathology of NAFLD is difficult to recognize or diagnose especially in early stages without a biopsy and therefore can remain undetected for significant time allowing the disease to progress. The diagnosis of NAFLD is crucial to be able to start adequate treatment including changes in diet and lifestyle in the first stage of the disease when the pathology is reversible and prevent the development of severe forms of the disease such as nonalcoholic steatohepatitis (NASH) or the irreversible cirrhosis stage. When the liver becomes damaged, this can lead to some metabolic alterations that have a severe and multifaceted impact in type 2 diabetes mellitus (T2DM), visceral obesity, and cardiovascular disease related to elevated plasmatic cholesterol, triglycerides, transaminases, and others that indicate hepatic disorders and oxidative stress. ... 000099078 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000099078 590__ $$a3.522$$b2020 000099078 591__ $$aGASTROENTEROLOGY & HEPATOLOGY$$b57 / 92 = 0.62$$c2020$$dQ3$$eT2 000099078 592__ $$a0.921$$b2020 000099078 593__ $$aGastroenterology$$c2020$$dQ2 000099078 593__ $$aMedicine (miscellaneous)$$c2020$$dQ2 000099078 593__ $$aHepatology$$c2020$$dQ2 000099078 655_4 $$ainfo:eu-repo/semantics/other$$vinfo:eu-repo/semantics/publishedVersion 000099078 700__ $$aAcín, S. 000099078 700__ $$aRamírez-Torres, A. 000099078 700__ $$0(orcid)0000-0002-0108-1004$$aNavarro, M.A.$$uUniversidad de Zaragoza 000099078 7102_ $$12008$$2640$$aUniversidad de Zaragoza$$bDpto. Produc.Animal Cienc.Ali.$$cÁrea Nutrición Bromatología 000099078 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole. 000099078 773__ $$g2020 (2020), 3495082 [2 pp]$$pCan. J. Gastroenterol. Hepatol.$$tCanadian Journal of Gastroenterology and Hepatology$$x2291-2789 000099078 8564_ $$s67318$$uhttps://zaguan.unizar.es/record/99078/files/texto_completo.pdf$$yVersión publicada 000099078 8564_ $$s2349118$$uhttps://zaguan.unizar.es/record/99078/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000099078 909CO $$ooai:zaguan.unizar.es:99078$$particulos$$pdriver 000099078 951__ $$a2024-01-18-09:11:26 000099078 980__ $$aARTICLE